0000950123-22-010618.txt : 20221101 0000950123-22-010618.hdr.sgml : 20221101 20221101065909 ACCESSION NUMBER: 0000950123-22-010618 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221101 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221101 DATE AS OF CHANGE: 20221101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE CENTRAL INDEX KEY: 0000874716 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010393723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19271 FILM NUMBER: 221348440 BUSINESS ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 BUSINESS PHONE: 2075560300 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 FORMER COMPANY: FORMER CONFORMED NAME: IDEXX CORP / DE DATE OF NAME CHANGE: 19600201 8-K 1 idxx-8k_20221101.htm 8-K idxx-8k_20221101.htm
false IDEXX LABORATORIES INC /DE 0000874716 0000874716 2022-11-01 2022-11-01

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 1, 2022 

IDEXX LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

 

000-19271

 

01-0393723

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

 

 

One IDEXX Drive, Westbrook, Maine

 

 

 

04092

(Address of principal executive offices)

 

 

 

(ZIP Code)

207. 556.0300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.10 par value per share

 

IDXX

 

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 

 

 


 

Item 2.02          Results of Operations and Financial Condition.

 

On November 1, 2022, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

Item 9.01          Financial Statements and Exhibits.

 

(d)Exhibits

 

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

 

Exhibit No.

 

Description of Exhibit

99.1

 

Press Release entitled “IDEXX Laboratories Announces Third Quarter Results,” issued by the Company on November 1, 2022.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IDEXX LABORATORIES, INC.

 

 

 

 

 

 

 

Date: November 1, 2022

 

 

 

By:

 

/s/ Brian P. McKeon

 

 

 

 

 

 

Brian P. McKeon

 

 

 

 

 

 

Executive Vice President,

Chief Financial Officer and Treasurer

 

 

 EX-99 2 d396244dex991.htm EX-99.1
Exhibit 99.1

IDEXX Laboratories Announces Third Quarter Results

  • Achieves third quarter revenue growth of 4% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 5% reported and 9% organic, building on high prior year growth
  • Continued strong demand for diagnostic services and excellent commercial execution support record third quarter premium instrument placements, driving 14% growth in global premium instrument installed base
  • Delivers EPS of $2.15, an increase of 6% as reported and 13% on a comparable basis supported by operating margin expansion of 120 basis points as reported and 100 basis points on a comparable basis
  • Adjusts 2022 revenue guidance to 3.5% - 4.5% growth as reported and 6.5% - 7.5% organic. At midpoint, reflects consistent reported revenue outlook as solid organic growth trends offset updated foreign exchange impacts
  • Updated EPS outlook of $7.74 - $7.98 reflects consistent operational outlook at midpoint, supported by strong second half comparable operating profit gains, and incorporates $0.05 combined impact from updated foreign currency exchange rate and interest rate projections

WESTBROOK, Maine, Nov. 1, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results and an update on U.S. companion animal diagnostics trends.

Third Quarter Results

The Company reports revenues of $842 million for the third quarter of 2022, a 4% increase as reported and 8% organically, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 5% reported and 9% organic, building on strong prior year performance. Results were supported by 10% reported and organic growth in U.S. CAG Diagnostics recurring revenues, reflecting continued benefits from strong IDEXX execution. Continued high companion animal sector demand and benefits from IDEXX innovation and commercial engagement drove record global premium instrument placements, which increased 10% compared to the prior year period. Veterinary software, services and diagnostic imaging systems revenue grew 14% as reported and 15% organically, supported by record quarterly placements of software solutions and a continued shift to cloud-based products. Overall revenue gains in the quarter were also supported by Water revenue growth of 7% reported and 12% organic.

Third quarter earnings per diluted share ("EPS") were $2.15, an increase of 6% as reported and 13% on a comparable basis, reflecting solid gross margin gains and controlled operating expense growth. EPS results included $0.08 per share negative impact from currency changes and no impact from tax benefits related to share-based compensation.

"Thanks to excellent execution by teams across the organization, IDEXX drove continued solid organic growth off elevated prior year levels in the third quarter," said Jay Mazelsky, President and Chief Executive Officer. "Record premium instrument placements in the quarter and gains across our business segments were supported by decades of innovation and strong customer engagement. By advancing our strategic priorities, IDEXX continues to help veterinarians deliver high standards of care in an efficient way as we pursue enduring growth aligned to the long-term global opportunity for companion animal diagnostics."

Companion Animal Diagnostics Trends Update

Continued elevated demand for companion animal healthcare supported solid gains in CAG diagnostic products and services. Average U.S. diagnostics revenue per practice grew 7% on a same-store basis in the third quarter, faster than 4% growth in overall clinic revenues. U.S. same-store clinical visits at veterinary practices declined 2.4%, a modest improvement compared to the prior quarter. Growth for pet healthcare including diagnostics has increased significantly from pre-pandemic levels reflecting compound annual growth of approximately 2.5% in clinical visits and 11% in same-store diagnostics revenues for the U.S. compared to the third quarter of 2019.

Additional U.S. companion animal practice key metrics are available in the Q3 2022 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

Third Quarter Performance Highlights

Companion Animal Group

The Companion Animal Group generated revenue growth of 4% reported and 8% organic for the quarter, supported by CAG Diagnostics recurring revenue growth of 5% on a reported basis and 9% organically. Continued solid growth was achieved across IDEXX's testing modalities, building off high levels in the prior year period. Record premium instrument placements were 10% higher than the prior year period, driving a 14% year-over-year increase in the global premium instrument installed base.

  • IDEXX VetLab® consumables generated 4% reported and 9% organic revenue growth, with solid organic gains across U.S. and international regions supported by benefits from an expanded global premium instrument installed base.
  • Reference laboratory diagnostic and consulting services generated 5% reported and 8% organic revenue growth, driven by strong gains in the U.S., which were moderated by modest organic revenue growth in international regions, reflecting pressure on same-store clinical visit growth in Europe — including macro-economic impacts.
  • Rapid assay products revenues grew 5% as reported and 7% organically, supported by net price gains.

Veterinary software, services and diagnostic imaging systems revenues grew 14% as reported and 15% organically, supported by double-digit organic gains in recurring software and digital imaging revenues. Strong demand for cloud-based products continues to support momentum in software solution placements and customer gains.

Water

Water revenues grew 7% on a reported basis and 12% on an organic basis for the quarter, reflecting solid volume growth across U.S. and international regions and benefits from net price gains.

Livestock, Poultry and Dairy ("LPD")

LPD revenues declined 2% as reported and grew 7% on an organic basis for the quarter, benefiting from growth in herd health screening revenues and improved results in China.

Gross Profit and Operating Profit

Gross profits increased 7% as reported and 10% on a comparable basis. Gross margin of 60.2% increased 180 basis points as reported and 120 basis points on a comparable basis. Benefits from net price gains, lab productivity initiatives and improvement in software service gross margins offset select inflationary effects.

Operating margin was 29.1% in the quarter, 120 basis points higher than the prior year as reported and 100 basis points higher on a comparable basis, reflecting gross margin gains and controlled year-over-year operating expense growth of 6% as reported and 9% on a comparable basis. As planned, operating expense growth was in line with revenue gains as we prioritized investments and gained leverage from prior commercial investments.

2022 Growth and Financial Performance Outlook

The Company is updating its full-year revenue growth outlook to 3.5% - 4.5% as reported and 6.5% - 7.5% organically. The narrowed organic revenue growth range reflects solid third quarter performance and a fourth quarter outlook consistent with prior guidance. Updated foreign exchange projections will reduce reported revenue by $10 million, compared to the prior outlook, as a stronger U.S. dollar is now projected to reduce full-year reported growth by approximately 4%. The updated outlook includes full-year CAG Diagnostics recurring revenue growth of 4% - 5% as reported and 7.5% - 8.5% organically, supported by continued benefits from strong IDEXX execution including additional second half price gains.

The Company updated its full-year reported operating margin outlook to 26.3% - 26.8%, reflecting consistent expectations for operating margin performance on a comparable basis and an estimated ~ 10 basis points in year-over-year net margin impact from updated foreign currency exchange rate estimates.

The Company's EPS outlook of $7.74 - $7.98 reflects an adjustment of $0.05 at midpoint, including $0.01 of negative impact from higher projected interest rates and $0.04 of negative impact related to the strengthening U.S. dollar.

The following table provides the Company's updated outlook for annual key financial metrics in 2022:

Amounts in millions except per share data and percentages 

Growth and Financial Performance Outlook

2022






Revenue

$3,325

-

$3,365

Reported growth

3.5 %

-

4.5 %

Organic growth

6.5 %

-

7.5 %

CAG Diagnostics Recurring Revenue Growth




Reported growth

4 %

-

5 %

Organic growth

7.5 %

-

8.5 %

Operating Margin


26.3 %

-

26.8 %

Operating margin expansion

  (270 bps)

-

(220 bps)

Impact of foreign exchange

~ 10 bps

Comparable margin expansion

  (280 bps)

-

(230 bps)

Impact of discrete in-license of technology

(230 bps)

EPS

$7.74

-

$7.98

Reported growth

(10 %)

-

(7 %)

Comparable growth

(4 %)

-

(1 %)

Other Key Metrics




Net interest expense

~ $39

Share-based compensation tax benefit

~ $8

Share-based compensation tax rate benefit

~ 1%

Effective tax rate

21.5 %

-

22 %

Share-based compensation EPS impact

~ $0.10

Reduction in average shares outstanding

~ 2%

Operating Cash Flow

85% - 90% of net income

Free Cash Flow

60% - 65% of net income

Capital Expenditures

~ $165

The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2022 and preliminary estimates for 2023.

Go-Forward Foreign Currency Exchange Rate Assumptions

2022












In U.S. dollars








euro

$0.96


British pound

$1.09


Canadian dollar

$0.72


Australian dollar

$0.62


Relative to the U.S. dollar








Japanese yen

¥148


Chinese renminbi

¥7.26


Brazilian real

R$5.28












Estimated Foreign Currency Exchange Rate Impacts

2022

2023










Revenue growth rate impact

(~ 4%)

(~ 3%)

CAG Diagnostics recurring revenue growth rate impact

(~ 4%)

(~ 3%)

Operating margin growth impact

~ 10 bps

(~ 70 bps)

EPS impact

(~ $0.25)

(~ $0.45)

EPS growth impact

(~ 3%)

(~ 6%)










Conference Call and Webcast Information

IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (EDT) to discuss its third quarter 2022 results and management's outlook. To participate in the conference call, dial 1-866-374-5140 or 1-404-400-0571 and reference pin 55765567. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year.

About IDEXX Laboratories, Inc.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs more than 10,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit www.idexx.com.

Note Regarding Forward-Looking Statements

This earnings release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are included above under "2022 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; and projected effective tax rates, reduction of average shares outstanding and net interest expense. These statements are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022, and September 30, 2022, as well as those described from time to time in the Company's other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company's consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company's business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company's business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and facilitates comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted third quarter 2022 results as follows: decreased gross profit growth by 3%, increased gross margin growth by 70 basis points, decreased operating expense growth by 3%, decreased operating profit growth by 4%, increased operating profit margin growth by 20 basis points, and decreased EPS growth by 4%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months and nine months ended September 30, 2022 and refer to the 2022 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2022 and 2023 projections and estimates.

Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that excludes the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three months and nine months ended September 30, 2022. Please refer to the 2022 Growth and Financial Performance Outlook section of this earnings release for estimated full-year 2022 organic revenue growth for the Company and CAG Diagnostics recurring revenue. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to increase projected full-year 2022 revenue growth by 50 basis points and to have no impact to projected full-year 2022 CAG Diagnostics recurring revenue growth.

Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

The reconciliation of these non-GAAP financial measures is as follows:

Three Months Ended

Year-over-Year

Nine Months Ended

Year-over-Year

September 30

September 30

Change

September 30

September 30

Change

Dollar amounts in thousands

2022

2021

2022

2021

Gross Profit (as reported)

$    506,626

$    472,921

7 %

$ 1,519,411

$ 1,433,011

6 %

Gross margin

60.2 %

58.4 %

           180 bps

59.8 %

59.4 %

              50 bps

Less: comparability adjustments









Change from currency

(15,044)

—

(33,660)

—

Comparable gross profit growth

$    521,670

$    472,921

10 %

$ 1,553,071

$ 1,433,011

8 %

Comparable gross margin and gross margin gain (or growth)

59.5 %

58.4 %

120 bps

59.4 %

59.4 %

              — bps









Operating expenses (as reported)

$    261,798

$    246,959

6 %

$    847,173

$    700,174

21 %

Less: comparability adjustments









Change from currency

$      (6,887)

—

$    (15,272)

—

Comparable operating expense growth

$    268,685

$    246,959

9 %

$    862,445

$    700,174

23 %









Income from operations (as reported)

$    244,828

$    225,962

8 %

$    672,238

$    732,837

(8) %

Operating margin

29.1 %

27.9 %

           120 bps

26.5 %

30.4 %

           (390) bps

Less: comparability adjustments









Change from currency

(8,156)

—

(18,389)

—

Comparable operating profit growth

$    252,984

$    225,962

12 %

$    690,627

$    732,837

(6) %

Comparable operating margin and operating margin gain (or growth)

28.9 %

27.9 %

           100 bps

26.4 %

30.4 %

           (400) bps

Amounts presented may not recalculate due to rounding.

Projected 2022 comparable operating margin expansion outlined in the 2022 Growth and Financial Performance Outlook section of this earnings release reflects projected full-year 2022 reported operating margin adjusted for estimated positive year-over-year foreign currency exchange rate change impact of approximately 10 basis points.

This impact and those described in the constant currency note above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2022 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company's business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

Three Months Ended

Year-over-Year

Nine Months Ended

Year-over-Year

September 30

September 30

Growth

September 30

September 30

Growth

2022

2021


2022

2021

Earnings per share (diluted)

$             2.15

$             2.03

6 %

$             5.97

$             6.71

(11) %

Less: comparability adjustments











Share-based compensation activity

0.00

0.05


0.10

0.29

Change from currency

(0.08)

—


(0.17)

—

Comparable EPS growth

2.23

1.98

13 %

6.04

6.42

(6) %

Amounts presented may not recalculate due to rounding.

Projected 2022 comparable EPS growth outlined in the 2022 Growth and Financial Performance Outlook section of this earnings release reflects adjustments including estimated positive share-based compensation activity of $0.10 and estimated negative year-over-year foreign currency exchange rate change impact of $0.25.

These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2022 reported EPS growth) to comparable EPS growth for the Company.

Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company's investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the nine months ended September 30, 2022 and 2021. To estimate projected 2022 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $165 million. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended September 30, 2022, we have deducted purchases of property and equipment of approximately $131 million from net cash provided from operating activities of approximately $580 million, divided by net income of approximately $670 million.

Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

IDEXX Laboratories, Inc. and Subsidiaries






Condensed Consolidated Statement of Operations






Amounts in thousands except per share data (Unaudited)










Three Months Ended

Nine Months Ended


September 30,

September 30,

September 30,

September 30,


2022

2021

2022

2021

Revenue:

Revenue

$841,661

$810,421

$2,538,756

$2,414,270

Expenses and
Income:

Cost of revenue

335,035

337,500

1,019,345

981,259

Gross profit

506,626

472,921

1,519,411

1,433,011

Sales and marketing

130,021

124,434

392,570

358,277

General and administrative

83,764

82,098

243,201

226,194

Research and development

48,013

40,427

211,402

115,703

Income from operations

244,828

225,962

672,238

732,837

Interest expense, net

(10,645)

(7,012)

(25,481)

(22,066)

Income before provision for income taxes

234,183

218,950

646,757

710,771

Provision for income taxes

53,245

43,772

139,875

128,698

Net Income:

Net income

180,938

175,178

506,882

582,073

Less: Noncontrolling interest in subsidiary's earnings

—

(57)

—

(1)

Net income attributable to stockholders

$180,938

$175,235

$506,882

$582,074

Earnings per share: Basic

$2.17

$2.06

$6.04

$6.82

Earnings per share: Diluted

$2.15

$2.03

$5.97

$6.71

Shares outstanding: Basic

83,247

85,123

83,855

85,325

Shares outstanding: Diluted

84,113

86,511

84,858

86,712

IDEXX Laboratories, Inc. and Subsidiaries






Selected Operating Information (Unaudited)










Three Months Ended

Nine Months Ended


September 30,

September 30,

September 30,

September 30,


2022

2021

2022

2021

Operating
Ratios

Gross profit

60.2 %

58.4 %

59.8 %

59.4 %

(as a percentage
of revenue):

Sales, marketing, general and administrative expense

25.4 %

25.5 %

25.0 %

24.2 %

Research and development expense

5.7 %

5.0 %

8.3 %

4.8 %

Income from operations1

29.1 %

27.9 %

26.5 %

30.4 %









1Amounts presented may not recalculate due to rounding.






IDEXX Laboratories, Inc. and Subsidiaries

Segment Information

Amounts in thousands (Unaudited)











Three Months Ended


September 30,
2022

Percent of
Revenue

September 30,
2021

Percent of
Revenue





Revenue:

CAG

$764,990


$732,495



Water

40,840


38,143



LPD

28,452


29,126



Other

7,379


10,657



Total

$841,661


$810,421












Gross Profit:

CAG

$456,334

59.7 %

$423,871

57.9 %

Water

29,406

72.0 %

26,694

70.0 %

LPD

17,462

61.4 %

16,848

57.8 %

Other

3,424

46.4 %

5,508

51.7 %

Total

$506,626

60.2 %

$472,921

58.4 %









Income from
Operations:

CAG

$221,454

28.9 %

$201,947

27.6 %

Water

$19,924

48.8 %

$17,599

46.1 %

LPD

$4,480

15.7 %

$3,600

12.4 %

Other

($1,030)

(14.0) %

$2,816

26.4 %

Total

$244,828

29.1 %

$225,962

27.9 %

IDEXX Laboratories, Inc. and Subsidiaries

Segment Information

Amounts in thousands (Unaudited)











Nine Months Ended


September 30,
2022

Percent of
Revenue

September 30,
2021

Percent of
Revenue





Revenue:

CAG

$2,310,261


$2,170,857



Water

116,406


109,374



LPD

89,211


101,920



Other

22,878


32,119



Total

$2,538,756


$2,414,270












Gross Profit:

CAG

$1,371,687

59.4 %

$1,277,531

58.8 %

Water

82,502

70.9 %

75,906

69.4 %

LPD

54,005

60.5 %

63,255

62.1 %

Other

11,217

49.0 %

16,319

50.8 %

Total

$1,519,411

59.8 %

$1,433,011

59.4 %









Income from
Operations:

CAG

$601,105

26.0 %

$649,892

29.9 %

Water

54,498

46.8 %

49,599

45.3 %

LPD

14,447

16.2 %

24,276

23.8 %

Other

2,188

9.6 %

9,070

28.2 %

Total

$672,238

26.5 %

$732,837

30.4 %

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)




























Three Months Ended











September 30,
2022

September 30,
2021

Dollar
Change

Reported
Revenue
Growth1

Percentage
Change from
Currency 

Percentage
Change from
Acquisitions

Organic
Revenue
Growth1

Net Revenue






CAG

$764,990

$732,495

$32,495

4.4 %

(4.1 %)

0.1 %

8.4 %

United States

530,758

484,903

45,855

9.5 %

—

—

9.4 %

International

234,232

247,592

(13,360)

(5.4 %)

(11.8 %)

0.4 %

6.0 %

Water

40,840

38,143

2,697

7.1 %

(5.2 %)

0.4 %

11.8 %

United States

20,940

19,216

1,724

9.0 %

—

—

9.0 %

International

19,900

18,927

973

5.1 %

(10.8 %)

0.9 %

15.0 %

LPD

28,452

29,126

(674)

(2.3 %)

(9.2 %)

—

6.9 %

United States

4,452

4,177

275

6.6 %

—

—

6.6 %

International

24,000

24,949

(949)

(3.8 %)

(10.8 %)

—

7.0 %

Other

7,379

10,657

(3,278)

(30.8 %)

(0.1 %)

—

(30.7 %)

Total Company

$841,661

$810,421

$31,240

3.9 %

(4.2 %)

0.1 %

7.9 %

United States

560,292

514,343

45,949

8.9 %

—

—

8.9 %

International

281,369

296,078

(14,709)

(5.0 %)

(11.4 %)

0.4 %

6.1 %













Three Months Ended











September 30,
2022

September 30,
2021

Dollar
Change

Reported
Revenue
Growth1

Percentage
Change from

Currency

Percentage
Change from
Acquisitions

Organic
Revenue

Growth1

Net CAG Revenue






CAG Diagnostics recurring revenue:

$667,309

$638,358

$28,951

4.5 %

(4.2 %)

0.2 %

8.6 %

IDEXX VetLab consumables

262,820

252,714

10,106

4.0 %

(5.4 %)

—

9.4 %

Rapid assay products

80,542

76,974

3,568

4.6 %

(1.9 %)

—

6.6 %

Reference laboratory diagnostic and consulting services

295,590

282,301

13,289

4.7 %

(3.6 %)

0.4 %

8.0 %

CAG Diagnostics services and accessories

28,357

26,369

1,988

7.5 %

(5.9 %)

—

13.4 %

CAG Diagnostics capital – instruments

35,176

39,401

(4,225)

(10.7 %)

(5.5 %)

—

(5.2 %)

Veterinary software, services and diagnostic imaging systems

62,505

54,736

7,769

14.2 %

(1.1 %)

—

15.3 %

Net CAG revenue

$764,990

$732,495

$32,495

4.4 %

(4.1 %)

0.1 %

8.4 %





























Three Months Ended












September 30,
2022

September 30,
2021

Dollar
Change

Reported
Revenue
Growth1

Percentage
Change from
Currency 

Percentage
Change from

Acquisitions

Organic

Revenue

Growth1









CAG Diagnostics recurring revenue:

$667,309

$638,358

$28,951

4.5 %

(4.2 %)

0.2 %

8.6 %

United States

$459,077

$418,728

$40,349

9.6 %

—

—

9.6 %

International

$208,232

$219,630

($11,398)

(5.2 %)

(12.0 %)

0.5 %

6.3 %

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)




























Nine Months Ended











September 30,
2022

September 30,
2021

Dollar
Change

Reported
Revenue
Growth1

Percentage
Change from
Currency 

Percentage
Change from
Acquisitions

Organic
Revenue
Growth1

Net Revenue






CAG

$2,310,261

$2,170,857

$139,404

6.4 %

(3.1 %)

0.9 %

8.6 %

United States

1,563,150

1,415,565

147,585

10.4 %

—

1.2 %

9.2 %

International

747,111

755,292

(8,181)

(1.1 %)

(8.8 %)

0.4 %

7.3 %

Water

116,406

109,374

7,032

6.4 %

(3.5 %)

0.1 %

9.8 %

United States

58,304

53,531

4,773

8.9 %

—

—

8.9 %

International

58,102

55,843

2,259

4.0 %

(6.9 %)

0.3 %

10.6 %

LPD

89,211

101,920

(12,709)

(12.5 %)

(5.2 %)

—

(7.3 %)

United States

12,054

11,441

613

5.4 %

—

—

5.4 %

International

77,157

90,479

(13,322)

(14.7 %)

(5.7 %)

—

(9.0 %)

Other

22,878

32,119

(9,241)

(28.8 %)

0.5 %

—

(29.2 %)

Total Company

$2,538,756

$2,414,270

$124,486

5.2 %

(3.2 %)

0.9 %

7.5 %

United States

1,646,023

1,502,219

143,804

9.6 %

—

1.1 %

8.5 %

International

892,733

912,051

(19,318)

(2.1 %)

(8.2 %)

0.4 %

5.7 %













Nine Months Ended











September 30,
2022

September 30,
2021

Dollar
Change

Reported

Revenue
Growth1

Percentage
Change from

Currency

Percentage
Change from

Acquisitions

Organic

Revenue

Growth1

Net CAG Revenue






CAG Diagnostics recurring revenue:

$2,017,532

$1,916,938

$100,594

5.2 %

(3.2 %)

0.2 %

8.2 %

IDEXX VetLab consumables

796,072

755,158

40,914

5.4 %

(4.0 %)

—

9.4 %

Rapid assay products

242,542

230,472

12,070

5.2 %

(1.5 %)

—

6.8 %

Reference laboratory diagnostic
and consulting services

894,795

851,757

43,038

5.1 %

(2.7 %)

0.4 %

7.3 %

CAG Diagnostics services and accessories

84,123

79,551

4,572

5.7 %

(4.3 %)

—

10.1 %

CAG Diagnostics capital – instruments

108,400

105,645

2,755

2.6 %

(4.9 %)

—

7.5 %

Veterinary software, services and
diagnostic imaging systems

184,329

148,274

36,055

24.3 %

(0.9 %)

11.0 %

14.3 %

Net CAG revenue

$2,310,261

$2,170,857

$139,404

6.4 %

(3.1 %)

0.9 %

8.6 %





























Nine Months Ended












September 30,
2022

September 30,
2021

Dollar
Change

Reported
Revenue

Growth1

Percentage

Change from
Currency 

Percentage
Change from
Acquisitions

Organic

Revenue

Growth1









CAG Diagnostics recurring revenue:

$2,017,532

$1,916,938

$100,594

5.2 %

(3.2 %)

0.2 %

8.2 %

United States

$1,351,936

$1,239,213

$112,723

9.1 %

—

0.1 %

9.0 %

International

$665,596

$677,725

($12,129)

(1.8 %)

(8.8 %)

0.5 %

6.5 %

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.


IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet

Amounts in thousands (Unaudited)


September 30, 2022

December 31, 2021



Assets:

Current Assets:





Cash and cash equivalents

$99,176

$144,454

Accounts receivable, net

388,072

368,348

Inventories

354,975

269,030

Other current assets

216,636

173,823

Total current assets

1,058,859

955,655

Property and equipment, net

612,405

587,667

Other long-term assets, net

968,803

893,881

Total assets

$2,640,067

$2,437,203

Liabilities and Stockholders'





Equity:

Current Liabilities:





Accounts payable

$110,144

$116,140

Accrued liabilities

405,992

458,909

Line of credit

633,000

73,500

Current portion of long-term debt

—

74,996

Deferred revenue

40,809

40,034

Total current liabilities

1,189,945

763,579

Long-term debt, net of current portion

760,814

775,205

Other long-term liabilities, net

213,309

208,427

Total long-term liabilities

974,123

983,632

Total stockholders' equity

475,999

689,992

Total liabilities and stockholders' equity

$2,640,067

$2,437,203

IDEXX Laboratories, Inc. and Subsidiaries

Select Balance Sheet Information (Unaudited)


September 30,
2022

June 30,
2022

March 31,
2022

December 31,

2021

September 30,
2021

Selected Balance Sheet Information:

Days sales outstanding1

43.4

43.2

42.0

42.4

42.7

Inventory turns2

1.3

1.5

1.6

2.0

1.9











1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

2Inventory turns represent inventory-related cost of product revenue for the twelve months preceding each quarter-end divided by the average inventory balances at the beginning and end of each quarter.

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Cash Flows

Amounts in thousands (Unaudited)


Nine Months Ended


September 30, 2022

September 30, 2021



Operating:

Cash Flows from Operating Activities:





Net income

$506,882

$582,073

Non-cash adjustments to net income

92,271

118,261

Changes in assets and liabilities

(229,597)

(154,752)

Net cash provided by operating activities

369,556

545,582

Investing:

Cash Flows from Investing Activities:





Purchases of property and equipment

(99,609)

(87,761)

Acquisition of intangible assets, businesses and equity investment

(46,512)

(161,166)

Net cash used by investing activities

(146,121)

(248,927)

Financing:

Cash Flows from Financing Activities:





Borrowings under revolving credit facilities, net

559,500

—

Payment of senior debt

(75,000)

(50,000)

Payments for the acquisition-related contingent consideration and holdbacks

(5,730)

(1,500)

Repurchases of common stock

(745,691)

(502,021)

Proceeds from exercises of stock options and employee stock

purchase plans

23,257

37,428

Shares withheld for statutory tax withholding payments on

restricted stock

(10,552)

(15,501)

Net cash used by financing activities

(254,216)

(531,594)

Net effect of changes in exchange rates on cash

(14,497)

(3,786)

Net decrease in cash and cash equivalents

(45,278)

(238,725)

Cash and cash equivalents, beginning of period

144,454

383,928

Cash and cash equivalents, end of period

$99,176

$145,203

IDEXX Laboratories, Inc. and Subsidiaries

Free Cash Flow

Amounts in thousands except per share data (Unaudited)


Nine Months Ended


September 30, 2022

September 30, 2021



Free Cash Flow:

Net cash provided by operating activities

$        369,556

$        545,582

Investing cash flows attributable to purchases of property and equipment

(99,609)

(87,761)

Free cash flow1

$        269,947

$        457,821





1See Statements Regarding Non-GAAP Financial Measures, above.

IDEXX Laboratories, Inc. and Subsidiaries






Common Stock Repurchases






Amounts in thousands except per share data (Unaudited)








Three Months Ended

Nine Months Ended

September 30, 2022

September 30, 2021

September 30, 2022

September 30, 2021



Shares repurchased in the open market

453

274

1,764

892

Shares acquired through employee surrender for statutory tax withholding

—

1

21

29

Total shares repurchased

453

275

1,785

921







Cost of shares repurchased in the open market

$        166,423

$        183,315

$        742,661

$        510,937

Cost of shares for employee surrenders

162

515

10,552

15,501

Total cost of shares

$        166,585

$        183,830

$        753,213

$        526,438







Average cost per share – open market repurchases

$          367.55

$          668.33

$          421.12

$          572.10

Average cost per share – employee surrenders

$          387.07

$          688.35

$          502.26

$          547.90

Average cost per share – total

$          367.56

$          668.38

$          422.07

$          571.36

CONTACT: John Ravis, Investor Relations, 1-207-556-8155



 GRAPHIC 3 d396244dlogo.jpg GRAPHIC begin 644 d396244dlogo.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_[0B@4&AO=&]S:&]P(#,N, X0DE-! 0 M "(0< E !P">@ "34D< FX "U!2($Y%5U-725)%' )T < F4 #55. M251%1"!35$%415,< E\ DU%' ): E715-40E)/3TL< AD "$-/3E-53452 M' )X" ,*(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @("!)1$586"!,86)O&EF !-30 J " $ M 3$ @ !$ ^41 0 $! 41$ ! $ "XC41( ! $ M "XC $%D;V)E($EM86=E4F5A9'D /_A%N9H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP M0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,2XP+6IC M,# S(CX*(" \"UN"UD969A=6QT(CXF(WA!.R @(" @(" @(" @(" @(" @(" @(" @("8C M>$$[(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @)B-X03L@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" F(WA!.R @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @("8C>$$[(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @)B-X03L@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" F(WA!.R @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M("8C>$$[(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @)B-X03L@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @("!)1$586"!,86)O$$[(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @)B-X03L@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" F(WA!.R @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @("8C>$$[(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @)B-X03L@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" F(WA!.R @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @("8C>$$[(" @(" @(" @(" @(" @(" @(" @(" @)B-X M03L@(" @(" @(" @(" @(" @(" @(#PO&UP;65T83X*(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P " M 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+"0@("@@'!PH- M"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'" P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\ M$0@ 20&0 P$B (1 0,1 ?_$ !X (" @,! 0 )!@@%!P$" M! ,*_\0 6! 0($ P,$"0T,"0(' 0(# 0%!@<1(0@2,4%15M()$Q@B M,D*!D944%1DV4F%B<762E+.T%A4V1Y4D1/K(VNL2B5R3N2DR\ M_3YJ7G9*;0'67V' MMU)X*2H:$0G&+ ;"6U9-8*WS+6_5II2K3K3X:4EQ7>T MY]9R2\GF23D%CAKO<0'.//'.\.=/GB0@@WASI\\&\.=/GB0@@WASI\\&\.=/ MGB0BU]H['C&/NQ9;% M&6]CTR.R5:_*-Z;^U.QE;"V)^0?I4\]*S++LO,RSBFG6G4%"VEI.2DJ!U!!T M(CXQ?O;LV*QBK)/W=:TLD7/+-YSZ WN(5% X]-'K$W;U6EI^1F7I.=DG4OL/M*W7&5I.:5)/(08K%* M]#R> F&Q[A1XCQ5:<"DGUXYCU:SI[*BW69QI6DRL'6601X@/AGQB-W@# MG4>%(-H@@B185865G&:^).WZ%+>J)Z;.94K,-R[8\)UP^*A/*>70#,D"$*/! MM105!*BE) )RT!.>69]_(^8QQ#/K!V-;.L_ V8LB8DD5&7J:0NHS:TA+\V^! MHZ#Q04'P /! Y75)T.FL8 M(UAPMFWA3;_M>1K-(FVIVFU%H/,/-G1:3_(@Y@@Z@@@ZB,G"XMB':Z=P N@4 M>LO.+M"JNYO9YJ];73IV](]R=-\#D[X:@YL9DYMJ?E6WV'&WF7DA;;B%!25I M(S!!&A!&N<"PY7TC36V-M5RFSA9(;E%,S-T55"DTZ55J&AP+[@]PD\!XRM.< MB4[1&/M(V=\.YBMU-0>F%YM2,FE63DZ\1F$#F XJ5XH!/'(%8&)>)%7Q;O:? MN"N3)F:A/KWE$:(:2/!;0/%0D: ?[DF*16L96ZW.7)6)JH5"9>G)Z==4_,/N MJWEO+43K* C1]Q)_ MQ"/!2?!!S/?$;L?V!MBGU]7)WW=TI_4D$/4>GO)_"#Q3,N)/B#BA)X^$=,L[ MN 90;2D)G@@@A"E&"/XZ;/\ ER2^T(AM_)Y84A@C^.FS_ER2^T(AM_)Y8.18 MD[71[9ZI^^O_ %JH\,;1N'9-Q,F;@J#K=CW$MMV:>6E0EQDH%Q1!\+FCQ]R- MB=T%N/Z..M"%A,#;9D[UQGM2CU%HOR%4JTO*S+864%;:U@*&8U&G*(O_ .QV MX3=')CTG,]>*E;/VS!B';>.UFU"?LVO2DC)5F6?F'W& $,H2X"I1.? "&20; M2D:0]CMPFZ.3'I.9Z\'L=N$W1R8])S/7C=\$'O'SF>Q MS83OM%*:#.-$^,BJ3.8\ZS&\X(MULJ/BIV*NC3=-=?LZN3TA.I25(EJDH/R[ MI]SO@!:/C[[XHIE>5G5/#ZZ)ZBUB4WI^KO/R3DK/F3:"MTMK!:*M1J0M8'O)]Z%*-BED!2% M@\#H8V+W(V)W06X_HXZT'Y?V,G]F;BX6P+9-;P^V=Y.F5ZG3E*GVIZ: M7ZGF4[JTH4X5).6? YDQ6_;AV>+ZO[:9K]5HMJ5JITV8:E0U,R[(4VX4RZ$J MR.?(01Y(,\RODK#'5\Y,.'E""?X1L?N1L3N@MQ_1QUHZO[(N)Y8< L2XR2D@ M?U<S*8*?I]R>A'HO?[3OI\?;%\6/BSZMZWY>7 MZ-^=SU870JU/1+'5B1V_;E/M.E-2%+D92G2+.?:Y>692TTC,DG)*0 ,R2?C, M5@]F4P4_3[D]"/193#V^I#$VQ:/<5+4ZNFUR3:GI4NMEM9:<2%))2=0AU)E9\UW>FUGPGK.DX8]74^USZ..5VESQN,M\]IO&8BH>WSL5& MX4SE]6C)YU%(+M7I[*=9L#B^VD?X@'A)'AC4=\#O6\@(SCS'SY,X.8S&H,$7 M'VW-@R[G4:3+)&\AQ1_MV4Z#=)\)(X$[PT) K[W(V)W06X M_HXZT.4-D6PWQ%JV%%Z2-?HDR96HT]>\A7%#B3X3:QXR%#0C_< Q:C:#[)"S M=6"\A(6DF9I]P5U@IJ;AS"J0GP5H;5XRUZ[JQP2<]%$ : [D;$[H+Y&Q.Z"W']''6CE&R'B>XM*18MQ9J( S82!Y25 M:?'&L0^QK&JN)-V2-#HDFY/5.HN=K9:1IGSJ4>"4I&I4= !#,=EC9AI6S79 ME62W.UR>"5U*H;N1?6."$9ZAM.9W1\9.IC$;'>R7);.%IF8FPS.754VQZNFD MC-+">/:&C[@'B?&(S.@ &Z(%IR"(GC1@U1<=;#FJ!7&.V2[_ '[3R,@[*.CP M76SR*&?Q$$@Y@F)9!&-*9QUP.K6S_?LQ0JRWO$9N2DTA)#4\SGD'$?R*>*3I MS$PV&N;0VS_1=HJP7J-54]JF&\W9&=0D%V1>RR"T\X/!2>"A[^1"];CV+<3K M=KTW(BT*M/B5=+8F9-L.,3 '!:%9C-)&NHS' ZB'*%C5L6DV)-N=C".AOVQ> M#\PNARK*WJ9,I27')4I!5ZFRXE*O$]RHY'O2-W4'*ENJ MTGPE#\RDC_61EX(.?PV5^Q_UZ]KW$W?5(G:);]-4E;DM,#<>J:N(;&1S#?NE M<3X(XDB_LC(LTR2:EI9IMB780&VFVTA*&T@9!( T T $&TI'T;;2T@)2 E* M1D !D (Y@@@D3/!!!'1S2C!'\=-G_+DE]H1#?!A8EP;9>*,K7Z@TW>M70VU-/(0D)9R2D.* '@I%Q7(T8;N>F[G':%R8 [6F)-T8Y6?3:A>%4FI"?K$M+S#*TM;KK:G % M).2,\B.:&-QEFS91!!!&-$$$$2$<*RY"0I2$N M9)'>@#(#3A%3MOV^:W1=JNXI:2K58DY=#,H4M,3SK3:;^$&2>;^$*%^^=+.1OIX M1^?*Z/;15/WU_P"M5#[\*WES.&5NN.+6XXNF2JE*4HJ4HEE!)).I,5MG>PS8 M.3\Z_,.?==VR8<4ZK*L$#-2BH^)SF/D/%6B]QJ$Z<[?;^G??>[>>WZ/WGT(^ MD;2?"F?>9:I,_P"[.GQXXR_X\]]][/\ :%*00V;V%O!G_-_ID]2#V%O!G_-_ MID]2/C_@3J/V?;_#]^^4?X1^;K?@G[RF8(;-["W@S_F_TR>I!["W@S_F_P!, MGJ1? G4?L^W^%\H_PC\W6_!/WE,G@?BAY^QA^25AK_\ 6:?]0B-+'L+>#)Z7 M^F3U(LYAS87//<'PC MI6/NTL5.F]7^:SU(V1FYHW>?!@[SX,*Y[M+%3IO6/FL]2#NTL5.F]8^:SU(W MBSD:-WGP8!NY^+"N>[2Q4Z;UCYK/4CZT_;=Q5I\^P_\ =E47^T.)<[6\VTIM MS(Y[JAN#-)X$9C3EBXKD:'!&M-F':6I.TE8J9^4W)2K2@2W4I JS5*N$<1RE MM61*5?&#J"(V7!(0001(1U.[GKNYQ&L7L6Z+@E8LY<%=F>T2DJ,D(3J[,N'P M6FT^,M1X#XR<@"87I?>WKB5=EVSM0D;AFZ%)3#F;$A*ALMRR!HE.:DDJ.7%1 MXG/0#(1LC+3,.\^#!WGP85SW:6*G3>L?-9ZD'=I8J=-ZQ\UGJ1O%G(T;O/@P M=Y\&%<]VEBITWK'S6>I!W:6*G3>L?-9ZD7%2.8HSLA]D'JE-NSU MEQ"JJY^FU-P"7JCZ4I5(.'0)<*0 6E<_BG4Z$Y7D;<2\V%)(4E0S!!S!$98V M5V@@@C&DSP001T6F9EXI*@TVEP%2L@"3D.80PSN^,(NF4K]#F?^.%CP9GGC+-VRF<=WQA%TRE M?H1G'=\81=,I7Z',_\<=)C;^P MC8:*A=[+F7BHD9DD_P#YPLK,\\&<7%0D'^D4/> &?.(I/?E]U7$R[Y^NUJ;5.U.HN=L>=(R'#()2."4I ' M1B((V1EH@S &9T U/O01N'8TV9IK:%Q+85,L."V*.ZEZIOD9)=RU3+I/*I>F M?,G,\HSUB\FQ78[N'^S':R'_ )6]R_L9/[,W!GF5\FDXZOC-AS]1 M7\H[00A-9PLQ2MF4PSMYIVXJ$VXW3)9*D*J#(4DAE ((WM#&?^^U:O26W_2+ M/6A0A8;)S+;9_P!(@]3-_FV_FB#Q+D;W]]JU>DMO^D6>M!]]JU>DMO\ I%GK M0H3U,W^;;^:(/4S?YMOYHBXKD;W]]JU>DMO^D6>M!]]JU>DMO^D6>M"A/4S? MYMOYH@]3-_FV_FB+BN1O?WVK5Z2V_P"D6>M&8I57E*[((FI&:EYR6>7,O+<<6MQQQ16M:U%2EDG,DDZDDZDGC'6".S+*YAY#; M:%N..*"4(0DJ4M1.0 U))T A"]ML6S/WG<,G2:7*NSU1J#H8EV&QFIQ9X#W MARDG0 $G018C: ['A4<)L&J?<%+FG:Q4*U#X9TWR/U1H#G8=QL.H*5 *2H M9$'4&#:4A-$$62V\MCPX.5IRZ[=EC]RM1=_K##:=*4\H\,N1I1/>^Y/>\"F* MVPA2?"#%VM8(7W*7!0ICM4W+'=<;7F6IMHGOFG!RI.7Q@Y$:B&XL9-SDFM0+LB]EF6U<_.%<%#(CE 4_$WP!QYK6SU?S-;I"^V-JR;G9 M-:LFIYG/,H5S$<4JXI/O$@Y8V4V&,+B%B#2<+;/GJ[6YMN2IT@WONN*U)Y E M(XJ43D !J28P=C[0EJWUA']VLO4V)>ALLJ=FW'U!*I%21W[;@Y%I.F7+F,L\ MQFOW:[VKY_:3O#<8[=)VO37#ZWR:M%.'AV]T>[(X#Q FJ7;C2'&)5YH#MLY,9$9HST[6V=5'QB-T>,1'=D/9:G=I*^@EX/2MLTQ: M55*;3H50!'($YFYHQ2*D M\O5SD3+NJ/C6%88-?C@M/Y9D_KT0T_D\L'(L2=;H4/NGJ>H_#7^7_JJC MP[XYQYXF5R^V2I?O;WUBH\4(4:WQSCSP;XYQYXDL$21K?'.//!OCG'GB2P1) M&M\>)+!$D:+B1Q4D>6,]9V&-R8A309H5!K%6<5^BRBW$CXU9;H\ MIC;>S;[8F/UQ##K6]K,I^R$&TI%),#>Q@5ZXIIF=OB;10Z>"%&1E7$NSCPYE M+&:&_)O'XHNI85@4?#&UI6BT*08IM-DTY-LM#3WU$G52B=2HYDGC&9' 01EK M9!"TNR(* VM[ES(_L9/[,W#+87=M\?E37#^RE/LZ(W%F2N^^.<>>#?'.//$E M@A"C6^.<>>#?'.//$E@B2-;XYQYX-\>+G88[5U.V:]AFUDM%BIB<%.DE*S"1ZJ=!>^M M?@],_<4?6NQEBE1JZ+JG[UN&>)+!&I&M](\8>>+K]CVV.C2T2F(%TRF4TL!VBR3R=6$D:3*P?'(\ 'P0 M=[B1E5&3_"VOVB?^X0VR5_!D?JC^4'*E(^D$$$$GCK]!D[HHLU3JA+,SDC.M M*9?8=3O(=0H9%)',1"T]L'97G-FV]]Z7#TS:]46I5.FE=\6CQ,NX?=I' ^,G M7B%9,XC1'9%OR;9GY1E/^\QLK+"W=\>)+!#!A6+AG96BS--:G9E MNGSKB'IB62Z0T^M&>XI2>!*JU93ZMV,K8L?A5A= M1\&[&D;?H1D49 G5QY9U4XL^,M1U)_V $2*"" 8BO6W/L@MXZ6X:_0F$ M(NZE-9)2G)/KFR->TJ/NQKN*/+FDZ'2PL!X&)$TS#*Y1];3J%M.M**%H6DI4 MA0.1!!U!!T(,= GRAPHIC 4 gawmipkux4zq000001.jpg GRAPHIC begin 644 gawmipkux4zq000001.jpg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end EX-101.SCH 5 idxx-20221101.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 idxx-20221101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Information, Former Legal or Registered Name Entity Information Former Legal Or Registered Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 idxx-20221101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 01, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 01, 2022
Entity Registrant Name IDEXX LABORATORIES INC /DE
Entity Central Index Key 0000874716
Entity Emerging Growth Company false
Entity File Number 000-19271
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 01-0393723
Entity Address, Address Line One One IDEXX Drive
Entity Address, City or Town Westbrook
Entity Address, State or Province ME
Entity Address, Postal Zip Code 04092
City Area Code 207
Local Phone Number 556.0300
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.10 par value per share
Trading Symbol IDXX
Security Exchange Name NASDAQ
XML 9 idxx-8k_20221101_htm.xml IDEA: XBRL DOCUMENT 0000874716 2022-11-01 2022-11-01 false IDEXX LABORATORIES INC /DE 0000874716 8-K 2022-11-01 DE 000-19271 01-0393723 One IDEXX Drive Westbrook ME 04092 207 556.0300 Not Applicable false false false false Common Stock, $0.10 par value per share IDXX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - idxx-8k_20221101.htm 19 idxx-8k_20221101.htm d396244dex991.htm idxx-20221101.xsd idxx-20221101_lab.xml idxx-20221101_pre.xml gawmipkux4zq000001.jpg http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "idxx-8k_20221101.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "idxx-8k_20221101.htm" ] }, "labelLink": { "local": [ "idxx-20221101_lab.xml" ] }, "presentationLink": { "local": [ "idxx-20221101_pre.xml" ] }, "schema": { "local": [ "idxx-20221101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "idxx", "nsuri": "http://www.idexx.com/20221101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "idxx-8k_20221101.htm", "contextRef": "C_0000874716_20221101_20221101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "idxx-8k_20221101.htm", "contextRef": "C_0000874716_20221101_20221101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "verboseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information Former Legal Or Registered Name", "terseLabel": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "verboseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.idexx.com/20221101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0000950123-22-010618-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950123-22-010618-xbrl.zip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